Upstream Bio, Inc. (UPB) has received a new Buy rating, initiated by Evercore ISI analyst, Cory Kasimov.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Cory Kasimov has given his Buy rating due to a combination of factors that highlight the potential of Upstream Bio, Inc.’s sole program, verekitug. The drug is targeting lucrative markets such as asthma and COPD, which have previously turned similar medications into blockbuster successes. Verekitug’s mechanism of action is well-validated, and it offers a more convenient dosing schedule compared to existing treatments, potentially leading to superior efficacy.
Recent positive clinical trial results further support the drug’s potential, particularly in the treatment of CRSwNP. With a significant Phase 2 asthma trial result expected in the first quarter of 2026, strong outcomes could act as a major catalyst for the stock. Kasimov’s analysis suggests that if verekitug shows comparable efficacy and safety to existing treatments but with fewer required injections, it could achieve widespread adoption and commercial success.